[SARS-CoV-2 vaccines - what the nephrologist should know]. / SARS-CoV-2-Impfungen Was muss der Nephrologe wissen?
Dtsch Med Wochenschr
; 146(7): 466-470, 2021 Apr.
Article
in German
| MEDLINE | ID: covidwho-1155718
ABSTRACT
Only fifteen months after the beginning of the COVID-19 pandemic, several vaccines are already available for clinical use. While the spike protein of SARS-CoV-2 constitutes the main target of all predominant SARS-CoV-2 vaccines, they work by different mechanisms (mRNA-based vaccines vs. vector-based vaccines vs. protein-based vaccines).Though there are slight differences regarding the level of protection against mild COVID-19, all five vaccines that have been through phase 3 trials were nearly 100â% effective in preventing severe or fatal cases of COVID-19. The side effects were of short duration.Patients with chronic kidney disease (or other significant comorbidities) were largely excluded from Phase 3 trials, which makes definite recommendations concerning their vaccination difficult. The vaccine's effectiveness may be reduced in that population due to a uremic immune defect and/or immunosuppressive medication. However, these patients have an increased risk for severe or fatal COVID-19, so that they may particularly benefit from the vaccine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Renal Insufficiency, Chronic
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
German
Journal:
Dtsch Med Wochenschr
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS